Prevalence And Risk Of Metabolic Syndrome In Patients With Systemic Lupus Erythematosus:A Meta-analysis

Background : The prevalence of metabolic syndrome(MetS)in systemic lupus erythematosus(SLE)had resulted in a wide range of estimates from 3.3% to 45.2%according to previous studies.However,the systematic review and statistical analysis in this area are currently lacking.It is necessary to estimate the pooled prevalence of MetS among the patients of SLE in order to formulate preventative strategies.Furthermore,the association between SLE and MetS is controversial and has not previously been comprehensively assessed.Purpose: To conduct a systematic review and meta-analysis assessing the prevalence of Met S in patients with SLE and the association between SLE and MetS.Method:We searched systematic databases from inception to March 2017,including PubMed,the Cochrane Library,EMBASE,Weipu database,Wanfang database and China National Knowledge Infrastructure for relevant English and Chinese studies.The pooled prevalence,the odds ratio(OR)and 95% confidence interval(CI)were calculated by Stata software.We performed stratified analyses on possible sources of bias,including areas difference,years of publication and the diagnostic criteria of MetS.Publication bias was assessed with Egger's test method.Results: In the study of the prevalence of MetS in patients with SLE,47 studies containing 8367 subjects were included.These studies were published from 2006 to 2016.The number of patients with SLE ranged from 30 to 1494.The prevalence of Met S in patients with SLE ranged from 3.3% to 45.2%.The pooled prevalence of MetS in patients with SLE was 26%(95% CI: 0.23-0.29).In the study of the relationship between SLE and Met S,24 studies involving 2744 cases and 3028 controls were included.Comparing to control,the risk of MetS of patients with SLE was 1.88 times higher(95%CI: 1.54-2.30,P = 0.000)and SLE was a risk for MetS.Publication biases were found in the meta-analysis of the prevalence of MetS in patients with SLE(t = 2.69,P = 0.010)and in the study of the association between SLE and MetS(t = 5.79,P = 0.000).Conclusion: The systematic review and meta-analysis demonstrated the prevalence of Met S in patients with SLE was 26% and the risk of MetS of patients with SLE was 1.88 times higher than that of controls indicating that SLE is a risk factor for MetS.